https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-72012-08-10 00:00:002019-02-15 08:53:36Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-602012-08-09 00:00:002019-02-15 08:53:37Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-82012-08-07 00:00:002019-02-15 08:48:47Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Clin. Exp. Pharmacol. Physiol. 2012 Aug;39(8):725-302012-08-01 00:00:002019-02-15 09:21:33Newcastle disease virus: a promising agent for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-912012-08-01 00:00:002012-08-01 00:00:00Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / Cancer Cell Int. 2012 Aug;12(1):352012-08-01 00:00:002012-08-01 00:00:00Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-31 / Br J Anaesth 2012 Nov;109(5):754-612012-07-31 00:00:002019-02-15 08:39:15Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-27 / Int J Hyperthermia 2012;28(7):597-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-27 / Int J Hyperthermia 2012;28(7):597-6042012-07-27 00:00:002012-07-27 00:00:00Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-18 / Viral Immunol. 2012 Aug;25(4):268-762012-07-18 00:00:002019-02-15 09:21:29Cell-type-specific innate immune response to oncolytic Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-222012-07-03 00:00:002019-02-15 09:18:19Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
